Egetis Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 44

Employees

  • Stock Symbol
  • EGTX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.12
  • (As of Friday Closing)

Egetis Therapeutics General Information

Description

Egetis Therapeutics AB is a Swedish orphan-drug pharmaceutical company focused on developing and commercializing treatments for rare diseases with unmet medical needs. Its product, Emcitate (tiratricol), became the first approved treatment for MCT8 deficiency and was launched in Germany, while FDA approval is being pursued in the U.S.

Contact Information

Website
www.egetis.com
Formerly Known As
Pled Pharma
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Klara Norra Kyrkogata 26
  • 111 22 Stockholm
  • Sweden
+46 08-679
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Klara Norra Kyrkogata 26
  • 111 22 Stockholm
  • Sweden
+46 08-679

Egetis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Egetis Therapeutics Stock Performance

As of 13-Nov-2026, Egetis Therapeutics’s stock price is $1.12. Its current market cap is $519M with 465M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.12 $1.12 $0.38 - $1.14 $519M 465M 2.56M -$0.12

Egetis Therapeutics Financials Summary

As of 30-Sep-2026, Egetis Therapeutics has a trailing 12-month revenue of $7.47M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 380,719 223,187 226,776 154,849
Revenue 7,471 6,351 4,359 5,419
EBITDA (49,732) (33,507) (31,108) (30,473)
Net Income (50,030) (34,861) (32,489) (30,755)
Total Assets 65,515 69,453 71,809 76,066
Total Debt 7,043 9,846 10,640 11,307
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Egetis Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Egetis Therapeutics‘s full profile, request access.

Request a free trial

Egetis Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Egetis Therapeutics AB is a Swedish orphan-drug pharmaceutical company focused on developing and commercializing treatme
Pharmaceuticals
Stockholm, Sweden
44 As of 2026

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Egetis Therapeutics Competitors (1)

One of Egetis Therapeutics’s competitors is AviadoBio, a Venture Capital-Backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AviadoBio Venture Capital-Backed London, United Kingdom
You’re viewing 1 of 1 competitors. Get the full list »

Egetis Therapeutics Patents

Egetis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022019973-A Methods and formulations for treating and / or protecting acute liver failure and other hepatotoxic conditions Active 11-Jan-2016
AU-2017208123-A1 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Active 11-Jan-2016
AU-2017208123-B2 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Active 11-Jan-2016
CA-3010915-A1 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Active 11-Jan-2016
CA-3010915-C Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions Active 11-Jan-2016 A61K31/555
To view Egetis Therapeutics’s complete patent history, request access »

Egetis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Egetis Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Egetis Therapeutics‘s full profile, request access.

Request a free trial

Egetis Therapeutics Acquisitions (1)

Egetis Therapeutics’s most recent deal was a Merger/Acquisition with Rare Thyroid Therapeutics for . The deal was made on 03-Nov-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Rare Thyroid Therapeutics 03-Nov-2020 Merger/Acquisition Drug Discovery
To view Egetis Therapeutics’s complete acquisitions history, request access »

Egetis Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Egetis Therapeutics’s complete esg history, request access »

Egetis Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Rare Thyroid Therapeutics Stockholm, Sweden 2013
Egetis Therapeutics Incentive Stockholm, Sweden 2012

Egetis Therapeutics FAQs

  • When was Egetis Therapeutics founded?

    Egetis Therapeutics was founded in 2006.

  • Where is Egetis Therapeutics headquartered?

    Egetis Therapeutics is headquartered in Stockholm, Sweden.

  • What is the size of Egetis Therapeutics?

    Egetis Therapeutics has 44 total employees.

  • What industry is Egetis Therapeutics in?

    Egetis Therapeutics’s primary industry is Pharmaceuticals.

  • Is Egetis Therapeutics a private or public company?

    Egetis Therapeutics is a Public company.

  • What is Egetis Therapeutics’s stock symbol?

    The ticker symbol for Egetis Therapeutics is EGTX.

  • What is the current stock price of Egetis Therapeutics?

    As of 13-Nov-2026 the stock price of Egetis Therapeutics is $1.12.

  • What is the current market cap of Egetis Therapeutics?

    The current market capitalization of Egetis Therapeutics is $519M.

  • What is Egetis Therapeutics’s current revenue?

    The trailing twelve month revenue for Egetis Therapeutics is $7.47M.

  • Who are Egetis Therapeutics’s competitors?

    AviadoBio is a competitor of Egetis Therapeutics.

  • What is Egetis Therapeutics’s annual earnings per share (EPS)?

    Egetis Therapeutics’s EPS for 12 months was -$0.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process